TP53 mutations in MCL: more therapy is not better

Cohen, Jonathon B.

doi:10.1182/blood-2017-08-803551

Cited by 15 publications

(4 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While real-world data have potentially demonstrated the benefit of upfront auto-SCT in some patients, a high recurrence rate, even after consolidation treatment, has been observed in patients harboring high-risk factors, including blastoid variant MCL or TP53 mutation 15 , 59 , 60 . Hence, an approach with intensified chemotherapy followed by frontline auto-SCT for young and fit patients might be justified, particularly in the era of novel agents and improved safety and accessibility of allo-SCT.…”

Section: Discussionmentioning

confidence: 99%

Stem cell transplant for mantle cell lymphoma in Taiwan

Wang

Hsieh

Hsiao

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Mantle cell lymphoma (MCL) is a B-cell lymphoma featuring an aggressive course and a progressive relapsing pattern. International guidelines recommend early consolidative autologous stem cell transplant (auto-SCT) for eligible patients while reserving allogeneic SCT (allo-SCT) as therapy for refractory cases. Since data describing the implementation of transplants in the Asian population with MCL are limited, we aimed to analyze post-SCT outcomes of 99 MCL patients from the Taiwan Bone Marrow Transplant Registry database. The median age was 56 years, and 11% of the patients had blastoid variant MCL. Ninety-four patients received auto-SCT, while 13 patients received allo-SCT, eight of which received allo-SCT after failing auto-SCT. Before auto-SCT, 52% of the patients were in their first complete remission (CR1). Overall, 37 patients (39%) relapsed after auto-SCT. The median post-auto-SCT progression-free survival and overall survival (OS) were 43.6 months and not reached, respectively. Blastoid variant MCL, transplant not received in CR1, and disease progression within 12 months post-auto-SCT independently predicted inferior OS in multivariable analysis. The median post-allo-SCT OS was 74 months. Two patients (15%) died of MCL recurrence post-allo-SCT. Three patients with refractory diseases were salvaged with ibrutinib or venetoclax to allo-SCT. Treatment strategies incorporating novel agents warrant further optimization.

show abstract

Section: Discussionmentioning

confidence: 99%

Stem cell transplant for mantle cell lymphoma in Taiwan

Wang

Hsieh

Hsiao

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…While real-world data have potentially demonstrated the bene t of upfront auto-SCT in some patients, a high recurrence rate, even after consolidation treatment, has been observed in patients harboring high-risk factors, including blastoid variant MCL or TP53 mutation 15,44,45 . Hence, an approach with intensi ed chemotherapy followed by frontline auto-SCT for young and t patients might be justi ed, particularly in the era of novel agents and improved safety and accessibility of allo-SCT.…”

Section: Discussionmentioning

confidence: 99%

Stem Cell Transplant for Mantle Cell Lymphoma in Taiwan

Wang

Hsieh

Hsiao

et al. 2021

Preprint

View full text Add to dashboard Cite

Mantle cell lymphoma (MCL) is a B-cell lymphoma featuring an aggressive course and a progressive relapsing pattern. International guidelines recommend early consolidative autologous stem cell transplant (auto-SCT) for eligible patients while reserving allogeneic SCT (allo-SCT) as second-line therapy for refractory cases. Since data describing the implementation of transplants in the Asian population with MCL are limited, we aimed to analyze post-SCT outcomes of 99 MCL patients from the Taiwan Bone Marrow Transplant Registry database. The median age was 56 years, and 11% of the patients had blastoid variant MCL. Ninety-four patients received auto-SCT, while 13 patients received allo-SCT, eight of which received allo-SCT after failing auto-SCT. Before auto-SCT, 52% of the patients were in their first complete remission (CR1). Overall, 37 patients (39%) relapsed after auto-SCT. The median post-auto-SCT progression-free survival and overall survival (OS) were 43.6 months and not reached, respectively. Blastoid variant MCL, transplant not received in CR1, and disease progression within 12 months post-auto-SCT independently predicted inferior OS in multivariate analysis. The median post-allo-SCT OS was 74 months. Two patients (15%) died of MCL recurrence post-allo-SCT. Three patients with refractory diseases were salvaged with ibrutinib or venetoclax to allo-SCT. Treatment strategies incorporating novel agents warrant further optimization.

show abstract

“…The University of Pennsylvania CART-BCMA demonstrated ORR of 62% in patients with high-risk cytogenetics including 67% with TP53 or del17p mutation. In vivo CAR-T expansion was higher with the use of cyclophosphamide conditioning and a trend towards benefit was observed with higher peak CAR-T levels although this was not statistically significant [157]. BCMA-targeted CAR-Ts have produced impressive results thus far.…”

Section: Car-t Cell Immunotherapy For Hematologic Malignanciesmentioning

confidence: 99%

Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies

et al. 2019

View full text Add to dashboard Cite

Harnessing the power of the immune system to recognize and eliminate cancer cells is a longtime exploration. In the past decade, monoclonal antibody (mAb)-based immune checkpoint blockade (ICB) and chimeric antigen receptor T (CAR-T) cell therapy have proven to be safe and effective in hematologic malignancies. Despite the unprecedented success of ICB and CAR-T therapy, only a subset of patients can benefit partially due to immune dysfunction and lack of appropriate targets. Here, we review the preclinical and clinical advances of CTLA-4 and PD-L1/PD-1-based ICB and CD19-specific CAR-T cell therapy in hematologic malignancies. We also discuss the basic research and ongoing clinical trials on emerging immune checkpoints (Galectin-9/Tim-3, CD70/CD27, LAG-3, and LILRBs) and on new targets for CAR-T cell therapy (CD22, CD33, CD123, BCMA, CD38, and CD138) for the treatment of hematologic malignancies.

show abstract

TP53 mutations in MCL: more therapy is not better

Cited by 15 publications

References 16 publications

Stem cell transplant for mantle cell lymphoma in Taiwan

Stem cell transplant for mantle cell lymphoma in Taiwan

Stem Cell Transplant for Mantle Cell Lymphoma in Taiwan

Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies

Contact Info

Product

Resources

About